Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer

Ying Zhou, Rui Wei, Ling Wang, Jie Li, Wei Wang, Guiying Jiang, Songwei Tan, Fei Li, Xueqian Wang, Xiangyi Ma, Ling XiJournal of Nanobiotechnology 2024 · DOI

This study, recently published in the Journal of Nanobiotechnology, presents a sophisticated "all-in-one" nanomedicine approach to treat ovarian cancer. By combining chemotherapy, a custom-engineered nano-vaccine, and immune checkpoint blockade, researchers have developed a system that effectively turns a tumor’s own debris into a potent immune stimulant.

TL;DR

Researchers developed a nanoparticle (NP-TP1@M-M) that captures tumor antigens released during chemotherapy and delivers them directly to the immune system. When combined with PD-L1 blockade, this "in situ" vaccine significantly inhibits ovarian cancer growth and extends survival in mouse models by transforming a "cold" immunosuppressive environment into an "active" one.

What Problem Does This Paper Address?

Ovarian cancer (OC) is the deadliest gynecological malignancy, largely because it is often diagnosed late and develops resistance to chemotherapy. While OC is technically "immunogenic" (meaning the immune system can recognize it), immunotherapy often fails.

The authors identify two main hurdles:

  1. The Immunosuppressive Microenvironment: The tumor creates a "shield" that prevents immune cells from attacking.
  2. Lack of Defined Antigens: Unlike some cancers with clear targets, OC is highly heterogeneous. It is difficult to design a "one-size-fits-all" vaccine because the specific proteins (antigens) that the immune system should attack vary between patients.

While chemotherapy kills tumor cells and releases "chemotherapy-associated antigens" (CAAs), these antigens are usually too sparse or weak to trigger a robust immune response on their own.

Methods

The team engineered a multi-functional nanoparticle based on PLGA (poly D, L-lactide-co-glycolide), a biocompatible polymer known for its ability to capture proteins.

  • The Core: Encapsulates MPLA (monophosphoryl lipid A), a powerful adjuvant that "wakes up" dendritic cells (DCs).
  • The Surface: Modified with two key molecules at an optimized 1:2 ratio:
  • TMTP1 Peptide: A tumor-homing peptide that helps the particles find and bind to tumor cells and metastases.
  • Mannose: A sugar that targets specific receptors on dendritic cells, ensuring the "vaccine" is eaten and processed by the right immune cells.
  • The Strategy: The researchers used a "triple-threat" protocol:
  • Cisplatin (DDP): Kills tumor cells to release antigens.
  • NP-TP1@M-M: Captures these released antigens in situ and carries them to the lymph nodes.
  • aPD-L1: An antibody that blocks the "off switch" (PD-L1) that tumors use to deactivate T cells.

Datasets

The study utilized several biological models and analytical techniques:

  • Cell Lines: ID8 (mouse ovarian cancer) and DC2.4 (dendritic cell line).
  • Animal Models: C57BL/6 mice used for both abdominal metastasis models and prophylactic (preventative) vaccine challenges.
  • Proteomics: Label-free mass spectrometry was used to identify the specific proteins captured by the nanoparticles, comparing the TMTP1-modified version against standard control particles.

Key Insights and Ideas

  • Optimized Targeting: The researchers found that a 1:2 ratio of TMTP1 to Mannose was the "Goldilocks" zone. Too much targeting peptide caused "space crowding," which actually reduced the particle's ability to capture antigens.
  • Superior Antigen Enrichment: Mass spectrometry revealed that the TMTP1-modified NPs didn't just capture more protein; they specifically enriched for neoantigens, DAMPs (damage-associated molecular patterns), and CAAs. For example, they captured 2,953 types of proteins compared to 2,490 in the control group, including specific markers like Dag1 and Tubb3.
  • Lymph Node "Drainage": In vivo imaging showed that these nanoparticles are highly efficient at migrating from the injection site to the lymph nodes—the "command centers" of the immune system—within 4 hours.

Key Results

  • Immune Activation: The nano-vaccine significantly increased the maturation of dendritic cells (marked by CD80+ and CD86+ expression) and the secretion of pro-inflammatory cytokines like IL-12p70, TNF-α, and IFN-γ.
  • Survival Breakthrough: In a mouse model of metastatic ovarian cancer, the triple combination (Chemo + NP + aPD-L1) resulted in a 37.5% survival rate beyond 180 days, whereas all mice in the control groups (chemo alone or chemo + aPD-L1) died much earlier.
  • Prophylactic Protection: When used as a preventative vaccine, the antigen-loaded nanoparticles successfully "trained" the immune system to resist a later challenge with live tumor cells, significantly slowing tumor growth.

Limitations and Future Work

The authors acknowledge that while the results are promising, the study was limited by a relatively small sample size in some animal cohorts, which may have affected the statistical significance of certain secondary metrics.

Furthermore, while the TMTP1 peptide is excellent at homing to tumors, the "antigen capture" still relies on the random release of proteins during chemotherapy. Future work may focus on even more precise antigen selection or adapting the platform for other "cold" tumors that currently resist immunotherapy. Translating these results from a mouse ID8 model to human clinical trials remains the ultimate hurdle.

Summary updated

Abstract

The mortality of ovarian cancer (OC) has long been the highest among gynecological malignancies. Although OC is considered to be an immunogenic tumor, the effect of immunotherapy is not satisfactory. The immunosuppressive microenvironment is one reason for this, and the absence of recognized effective antigens for vaccines is another. Chemotherapy, as one of the most commonly used treatment for OC, can produce chemotherapy-associated antigens (CAAs) during treatment and show the effect of in situ vaccine. Herein, we designed an antigen capture nano-vaccine NP-TP1@M-M with tumor targeting peptide TMTP1 and dendritic cell (DC) receptor mannose assembled on the surface and adjuvant monophosphoryl lipid A (MPLA) encapsulated in the core of poly (D, L-lactide-co-glycolide) (PLGA) nanoparticles. PLGA itself possessed the ability of antigen capture. TMTP1 was a tumor-homing peptide screened by our research team, which held extensive and excellent tumor targeting ability. After these modifications, NP-TP1@M-M could capture and enrich more tumor-specific antigens after chemotherapy, stimulate DC maturation, activate the adaptive immunity and combined with immune checkpoint blockade to maximize the release of the body’s immune potential, providing an eutherapeutic strategy for the treatment of OC.
BibTeX
@article{zhou2024tumor,
  author = {Ying Zhou and Rui Wei and Ling Wang and Jie Li and Wei Wang and Guiying Jiang and Songwei Tan and Fei Li and Xueqian Wang and Xiangyi Ma and Ling Xi},
  title = {{Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer}},
  journal = {Journal of Nanobiotechnology},
  year = {2024},
  doi = {10.1186/s12951-024-02744-6},
}
Figure